Skip to content

Research & Literature

Last updated:

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature

Visualize citation networks across 53 referenced papers

Top Authors

Top Institutions

References

  1. 1

    Clinical Features of Imported Loiasis: A Case Series from the Hospital for Tropical Diseases, London.

    Saito M, Armstrong M, Boadi S, et al.

    The American journal of tropical medicine and hygiene 2015; (93(3)):607-11 doi:10.4269/ajtmh.15-0214.

    PMID: 26101271
  2. 2

    The relationship between microfilaraemic and amicrofilaraemic loiasis involving co-infection with Mansonella perstans and clinical symptoms in an exposed population from Gabon.

    Bouyou Akotet MK, Owono-Medang M, Mawili-Mboumba DP, et al.

    Journal of helminthology 2016; (90(4)):469-75 doi:10.1017/S0022149X15000607.

    PMID: 26268068
  3. 3

    Loa loa in the vitreous cavity of the eye.

    Nayak B, Sinha S, Nayak L

    BMJ case reports 2016; (2016()).

    PMID: 26746839
  4. 4

    Therapeutic apheresis using a mononuclear cell program to lower the microfilaria burden of a 23-year-old African woman with loiasis.

    Zhao Y, Alexander B, Bailey JA, et al.

    Journal of clinical apheresis 2017; (32(3)):200-202 doi:10.1002/jca.21479.

    PMID: 27302472
  5. 5

    Anterior Chamber Live Loa loa: Case Report.

    Kagmeni G, Cheuteu R, Bilong Y, Wiedemann P

    Clinical medicine insights. Case reports 2016; (9()):55-6 doi:10.4137/CCRep.S40012.

    PMID: 27441005
  6. 6

    Excess mortality associated with loiasis: a retrospective population-based cohort study.

    Chesnais CB, Takougang I, Paguélé M, et al.

    The Lancet. Infectious diseases 2017; (17(1)):108-116 doi:10.1016/S1473-3099(16)30405-4.

    PMID: 27777031
  7. 7

    Loa loa vectors Chrysops spp.: perspectives on research, distribution, bionomics, and implications for elimination of lymphatic filariasis and onchocerciasis.

    Kelly-Hope L, Paulo R, Thomas B, et al.

    Parasites & vectors 2017; (10(1)):172 doi:10.1186/s13071-017-2103-y.

    PMID: 28381279
  8. 8

    Case Report: Probable Case of Spontaneous Encephalopathy Due to Loiasis and Dramatic Reduction of Loa loa Microfilariaemia with Prolonged Repeated Courses of Albendazole.

    Arrey-Agbor DB, Nana-Djeunga HC, Mogoung-Wafo AE, et al.

    The American journal of tropical medicine and hygiene 2018; (99(1)):112-115 doi:10.4269/ajtmh.17-0664.

    PMID: 29741149
  9. 9

    Removal of adult subconjunctival Loa loa amongst urban dwellers in Nigeria.

    Okonkwo ON, Hassan AO, Alarape T, et al.

    PLoS neglected tropical diseases 2018; (12(11)):e0006920 doi:10.1371/journal.pntd.0006920.

    PMID: 30427837
  10. 10

    Environmental factors associated with the distribution of Loa loa vectors Chrysops spp. in Central and West Africa: seeing the forest for the trees.

    Badia-Rius X, Betts H, Molyneux DH, Kelly-Hope LA

    Parasites & vectors 2019; (12(1)):72 doi:10.1186/s13071-019-3327-9.

    PMID: 30728063
  11. 11

    Mouse models of Loa loa.

    Pionnier NP, Sjoberg H, Chunda VC, et al.

    Nature communications 2019; (10(1)):1429 doi:10.1038/s41467-019-09442-0.

    PMID: 30926803
  12. 12

    Encephalopathy in a patient with loiasis treated with albendazole: A case report.

    Volpicelli L, De Angelis M, Morano A, et al.

    Parasitology international 2020; (75()):102006 doi:10.1016/j.parint.2019.102006.

    PMID: 31676328
  13. 13

    Atypical Clinical Manifestations of Loiasis and Their Relevance for Endemic Populations.

    Buell KG, Whittaker C, Chesnais CB, et al.

    Open forum infectious diseases 2019; (6(11)):ofz417 doi:10.1093/ofid/ofz417.

    PMID: 31696139
  14. 14

    Imported loiasis in France: a retrospective analysis of 167 cases with comparison between sub-Saharan and non sub-Saharan African patients.

    Bouchaud O, Matheron S, Loarec A, et al.

    BMC infectious diseases 2020; (20(1)):63 doi:10.1186/s12879-019-4740-6.

    PMID: 31959110
  15. 15

    Loa loa filariasis in a tropical savanna area: report of one case in Ouagadougou.

    Ouédraogo NA, Korsaga-Somé N, Traoré F, et al.

    International journal of dermatology 2020; (59(4)):482-483 doi:10.1111/ijd.14782.

    PMID: 31975376
  16. 16

    Loiasis in sub-Saharan migrants living in Spain with emphasis of cases from Equatorial Guinea.

    Puente S, Ramírez-Olivencia G, Lago M, et al.

    Infectious diseases of poverty 2020; (9(1)):16 doi:10.1186/s40249-020-0627-4.

    PMID: 32029005
  17. 17

    Infection-associated Immune Perturbations Resolve 1 Year Following Treatment for Loa loa.

    Herrick JA, Makiya MA, Holland-Thomas N, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (72(5)):789-796 doi:10.1093/cid/ciaa137.

    PMID: 32055862
  18. 18

    Performance of two serodiagnostic tests for loiasis in a Non-Endemic area.

    Gobbi F, Buonfrate D, Boussinesq M, et al.

    PLoS neglected tropical diseases 2020; (14(5)):e0008187 doi:10.1371/journal.pntd.0008187.

    PMID: 32453734
  19. 19

    Burden of disease in Gabon caused by loiasis: a cross-sectional survey.

    Veletzky L, Hergeth J, Stelzl DR, et al.

    The Lancet. Infectious diseases 2020; (20(11)):1339-1346 doi:10.1016/S1473-3099(20)30256-5.

    PMID: 32585133
  20. 20

    Nonsurgical management of photoaversive ocular and systemic loiasis in Michigan.

    Padidam S, Trinh H, Lin X, Boss JD

    GMS ophthalmology cases 2020; (10()):Doc22 doi:10.3205/oc000149.

    PMID: 32676267
  21. 21

    [Loiasis (African eye worm): about a case].

    Adam ND, Soumana Y, Saley A, Saley I

    The Pan African medical journal 2020; (36()):302 doi:10.11604/pamj.2020.36.302.25124.

    PMID: 33282085
  22. 22

    Preliminary comparison between an in-house real-time PCR vs microscopy for the diagnosis of Loa loa and Mansonella perstans.

    Formenti F, Tang TT, Tamarozzi F, et al.

    Acta tropica 2021; (216()):105838 doi:10.1016/j.actatropica.2021.105838.

    PMID: 33484727
  23. 23

    [Long-lasting souvenir from Cameroon - Persistent, massive hypereosinophilia in amicrofilaremic infection with Loa loa].

    Meffert L, Schmitz F, Ziob J

    Deutsche medizinische Wochenschrift (1946) 2021; (146(15)):1005-1008 doi:10.1055/a-1500-6375.

    PMID: 34344038
  24. 24

    A Case of Possible Loiasis Contracted in Cameroon and Diagnosed in Milan, Italy, and Review of Cases Published in Dermatological Journals.

    Lunardon L, Romagnuolo M, Cusini M, Veraldi S

    Case reports in dermatology 2021; (13(2)):389-393 doi:10.1159/000513939.

    PMID: 34413738
  25. 25

    Evaluation of LAMP for the diagnosis of Loa loa infection in dried blood spots compared to PCR-based assays and microscopy.

    Ta-Tang TH, Berzosa P, Rubio JM, et al.

    Memorias do Instituto Oswaldo Cruz 2022; (116()):e210210 doi:10.1590/0074-02760210210.

    PMID: 35170676
  26. 26

    Spleen nodules in Loa loa infection: re-emerging knowledge and future perspectives.

    Tamarozzi F, Buonfrate D, Ricaboni D, et al.

    The Lancet. Infectious diseases 2022; (22(7)):e197-e206 doi:10.1016/S1473-3099(21)00632-0.

    PMID: 35219405
  27. 27

    The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria vaccine trial in Equatorial Guinea.

    Manock SR, Nsue VU, Olotu A, et al.

    Transactions of the Royal Society of Tropical Medicine and Hygiene 2022; (116(8)):745-749 doi:10.1093/trstmh/trac019.

    PMID: 35394038
  28. 28

    Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis.

    Ehrens A, Hoerauf A, Hübner MP

    GMS infectious diseases 2022; (10()):Doc02 doi:10.3205/id000079.

    PMID: 35463816
  29. 29

    A call for loiasis to be added to the WHO list of neglected tropical diseases.

    Jacobsen KH, Andress BC, Bhagwat EA, et al.

    The Lancet. Infectious diseases 2022; (22(10)):e299-e302 doi:10.1016/S1473-3099(22)00064-0.

    PMID: 35500592
  30. 30

    The Human Filaria Loa loa: Update on Diagnostics and Immune Response.

    Dieki R, Nsi-Emvo E, Akue JP

    Research and reports in tropical medicine 2022; (13()):41-54 doi:10.2147/RRTM.S355104.

    PMID: 35936385
  31. 31

    Factors associated with the periodicity of Loa loa microfilaremia in the Republic of the Congo.

    Campillo JT, Louya F, Bikita P, et al.

    Parasites & vectors 2022; (15(1)):417 doi:10.1186/s13071-022-05541-y.

    PMID: 36352480
  32. 32

    Profile of loiasis infection through clinical and laboratory diagnostics: the importance of biomarkers.

    Dieki R, Eyang Assengone ER, Nsi Emvo E, Akue JP

    Transactions of the Royal Society of Tropical Medicine and Hygiene 2023; (117(5)):349-357 doi:10.1093/trstmh/trac116.

    PMID: 36520072
  33. 33

    Excess Mortality Associated With Loiasis: Confirmation by a New Retrospective Cohort Study Conducted in the Republic of Congo.

    Hemilembolo MC, Niama AC, Campillo JT, et al.

    Open forum infectious diseases 2023; (10(3)):ofad103 doi:10.1093/ofid/ofad103.

    PMID: 36968967
  34. 34

    Association between altered cognition and Loa loa microfilaremia: First evidence from a cross-sectional study in a rural area of the Republic of Congo.

    Checkouri T, Missamou F, Pion SDS, et al.

    PLoS neglected tropical diseases 2023; (17(6)):e0011430 doi:10.1371/journal.pntd.0011430.

    PMID: 37339123
  35. 35

    Association between blood Loa loa microfilarial density and proteinuria levels in a rural area of the Republic of Congo (the MorLo project): a population-based cross-sectional study.

    Campillo JT, Hemilembolo MC, Pion SDS, et al.

    The Lancet. Microbe 2023; (4(9)):e704-e710 doi:10.1016/S2666-5247(23)00142-8.

    PMID: 37480932
  36. 36

    The African eye worm: current understanding of the epidemiology, clinical disease, and treatment of loiasis.

    Ramharter M, Butler J, Mombo-Ngoma G, et al.

    The Lancet. Infectious diseases 2024; (24(3)):e165-e178 doi:10.1016/S1473-3099(23)00438-3.

    PMID: 37858326
  37. 37

    Association between arterial stiffness and Loa loa microfilaremia in a rural area of the Republic of Congo: A population-based cross-sectional study (the MorLo project).

    Campillo JT, Dupasquier V, Lebredonchel E, et al.

    PLoS neglected tropical diseases 2024; (18(1)):e0011915 doi:10.1371/journal.pntd.0011915.

    PMID: 38241411
  38. 38

    Imported Loiasis at a Clinical Reference Center in Germany: A Retrospective Case Series.

    Nordmann T, Ruge J, Tappe D, Ramharter M

    The American journal of tropical medicine and hygiene 2024; (111(3)):521-525 doi:10.4269/ajtmh.24-0022.

    PMID: 38981492
  39. 39

    Clinical and epidemiological features of imported loiasis in Beijing: a report from patients returned from Africa.

    Li X, Huang M, Bi K, et al.

    BMC infectious diseases 2024; (24(1)):714 doi:10.1186/s12879-024-09620-6.

    PMID: 39033158
  40. 40

    A picture speaks a thousand words: A case of ocular Loa loa.

    Abdalla A, Jaafar SD, Abdalla H, et al.

    IDCases 2024; (38()):e02088 doi:10.1016/j.idcr.2024.e02088.

    PMID: 39494037
  41. 41

    Variability of Loa loa microfilarial counts in successive blood smears and its potential implication in drug-related serious adverse events.

    Lepage TM, Campillo JT, Louya F, et al.

    Parasites & vectors 2024; (17(1)):457 doi:10.1186/s13071-024-06494-0.

    PMID: 39516832
  42. 42

    Incidence of loiasis clinical manifestations in a rural area of the Republic of Congo: Results from a longitudinal prospective study (the MorLo project).

    Campillo JT, Pakat-Pambou BM, Sahm B, et al.

    PLoS neglected tropical diseases 2025; (19(2)):e0012868 doi:10.1371/journal.pntd.0012868.

    PMID: 39937767
  43. 43

    Revisiting the Loa loa microfilaremia thresholds above which serious adverse events may occur with ivermectin treatment.

    Boullé C, Pion SD, Gardon J, et al.

    PLoS neglected tropical diseases 2025; (19(3)):e0012957 doi:10.1371/journal.pntd.0012957.

    PMID: 40153701
  44. 44

    Treatment of loiasis: a review of clinical management recommendations.

    Ekoka Mbassi D, Dreeßen R, Zoleko Manego R, et al.

    Infectious diseases of poverty 2025; (14(1)):35 doi:10.1186/s40249-025-01300-0.

    PMID: 40336051
  45. 45

    Antifilarial treatment strategies: a systematic review and network meta-analysis.

    Albadrani MS, Molla A, Elbadawy HM, et al.

    BMC infectious diseases 2025; (25(1)):712 doi:10.1186/s12879-025-11105-z.

    PMID: 40380307
  46. 46

    Diagnosis, management and prevention of loiasis: guideline of the German Society for Tropical Medicine, Travel Medicine, and Global Health (DTG).

    Ramharter M, Schlabe S, Hübner MP, et al.

    Infection 2025; (53(3)):851-872 doi:10.1007/s15010-024-02443-2.

    PMID: 40397272
  47. 47

    Fortuitous discovery of a microfilaria of the genus Loa loa during a routine blood smear at the Hematology Laboratory of the Mohamed V Military Instruction Hospital in Rabat: a case report.

    Labrigui M, Layat H, Bouikhif M, et al.

    Access microbiology 2025; (7(5)) doi:10.1099/acmi.0.000895.v3.

    PMID: 40406564
  48. 48

    Delayed-Onset Loiasis: A Case of Loa loa Infection Diagnosed Six Years Post-exposure.

    Root HN, Bueno D, Bathurst N, Wieting M

    Cureus 2025; (17(6)):e86135 doi:10.7759/cureus.86135.

    PMID: 40672032
  49. 49

    Protective efficacy of skin-applied arthropod repellents against Chrysops bites in a Loa loa hyperendemic region in Gabon: A placebo-controlled randomized clinical trial of DEET, icaridin, citriodiol, and IR3535.

    Doumba Ndalembouly AG, Boussougou-Sambe ST, Ngossanga B, et al.

    Travel medicine and infectious disease 2025; (67()):102899 doi:10.1016/j.tmaid.2025.102899.

    PMID: 40885295
  50. 50

    Disability and quality of life assessment using WHODAS-12 items 2.0 and EQ-5D-5L in a rural area endemic for loiasis in the Republic of Congo: A population-based cross-sectional study (the MorLo project).

    Hemilembolo MC, Campillo JT, Dupasquier V, et al.

    PLoS neglected tropical diseases 2025; (19(9)):e0013491 doi:10.1371/journal.pntd.0013491.

    PMID: 40953102
  51. 51

    Loa loa Encephalopathy Following Treatment With Benzimidazole Derivatives: A Systematic Review.

    Davi SD, Nordmann T, Endamne LR, et al.

    Open forum infectious diseases 2025; (12(12)):ofaf700 doi:10.1093/ofid/ofaf700.

    PMID: 41377593
  52. 52

    Ocular filariasis manifesting as an orbital cellulitis and conjunctival nodule: a case report.

    Albou J, Chotard G

    Orbit (Amsterdam, Netherlands) 2026; 1 doi:10.1080/01676830.2025.2609909.

    PMID: 41498296
  53. 53

    Assessment of the efficacy and safety of two albendazole regimens for the treatment of hypermicrofilaraemic loiasis in adults in Woleu-Ntem Province, Gabon: A phase IIb single-blind randomised controlled trial.

    M'Bondoukwé NP, Ndong Akomezoghe L, Moutombi Ditombi BC, et al.

    PLoS neglected tropical diseases 2026; (20(1)):e0013166 doi:10.1371/journal.pntd.0013166.

    PMID: 41557726